Showing results (101-110 of 284) with videos related to
Sort By:
Pageof 29
Neuropsychobiology|August 20, 2005
Morphological abnormalities in nitric-oxide-synthase-positive striatal interneurons of schizophrenic patientsMartin Lauer, Silvia Johannes, Sabrina Fritzen, et al.Therapeutic Drug Monitoring|December 25, 2013
The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysisStefan Unterecker, Florian Proft, Peter Riederer, et al.FEBS Letters|January 22, 2002
The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's diseaseLuigi Zecca, Ruggero Fariello, Peter Riederer, et al.European Journal of Pharmacology|May 22, 2002
Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin?Peter Riederer, Paul Foley, Gerhard Bringmann, et al.International Review of Neurobiology|October 6, 2011
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's diseaseOrly Weinreb, Tamar Amit, Peter Riederer, et al.Annals of the New York Academy of Sciences|April 24, 2004
The relevance of iron in the pathogenesis of Parkinson's diseaseMario E Götz, Kay Double, Manfred Gerlach, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|September 3, 2024
Therapeutic drug monitoring in Parkinson's diseaseThomas Müller, Manfred Gerlach, Gudrun Hefner, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2011
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's diseaseManfred Gerlach, Gerd D Bartoszyk, Peter Riederer, et al.Stress (Amsterdam, Netherlands)|November 26, 2009
Chronic exogenous corticosterone administration generates an insulin-resistant brain state in ratsJelena Osmanovic, Konstanze Plaschke, Melita Salkovic-Petrisic, et al.Therapeutic Drug Monitoring|May 14, 2013
Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopramElnaz Ostad Haji, Klaus Mann, Aleksandra Dragicevic, et al.Pageof 29